Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director | September 22, 2006 | September 26, 2006 |
| DEERE & CODE · Entity 106 | Director | March 01, 2006 | April 04, 2006 |
| ManpowerGroup Inc.MAN · Entity 1769 | Director | January 01, 2019 | January 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date September 22, 2006 · Filed September 26, 2006
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 30,268 |
Ending reported balance
After 2006-09-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2006-09-22 · Exercise / conversion · Acquired 1,870 · Balance 28,472 Row 2 · 2006-09-22 · Exercise / conversion · Acquired 1,796 · Balance 30,268 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.23 · Expires 2006-09-29 | Direct | 0 |
Reported balance
After 2006-09-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2006-09-22 · Exercise / conversion · Disposed 1,870 · Balance 0 F3: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.20 · Expires 2006-12-30 | Direct | 0 |
Reported balance
After 2006-09-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2006-09-22 · Exercise / conversion · Disposed 1,796 · Balance 0 F3: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy wife | 4,590 |
Reported balance
Holding disclosure · report date 2006-09-22 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,590 F1: The reporting person disclaims beneficial ownership of all securities held by his wife and daughter. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy daughter | 400 |
Reported balance
Holding disclosure · report date 2006-09-22 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 400 F1: The reporting person disclaims beneficial ownership of all securities held by his wife and daughter. F2: By wife as custodian for minor daughter under the Uniform Gifts to Minor Act. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person disclaims beneficial ownership of all securities held by his wife and daughter.
F2: By wife as custodian for minor daughter under the Uniform Gifts to Minor Act.
F3: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program.
DEERE & CO
Report date March 01, 2006 · Filed April 04, 2006
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| $1 Par Common StockSEC Table I · non-derivative | Direct | 13,272 |
Reported balance
After 2006-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2006-03-01 · Grant · Acquired 974 · Balance 13,272 F1: References to Deere & Company common stock include associated preferred stock rights. F2: Includes 13,272 shares of restricted stock acquired under the Nonemployee Director Stock Ownership Plan of the issuer. Restrictions are as authorized by the Board of Directors. The plan provides for tax withholding rights. F3: The reporting person also indirectly beneficially owns 900 common shares of the issuer through a trust. The reporting person disclaims beneficial ownership of these shares. |
Filing footnotes · ownership attribution and instrument terms
F1: References to Deere & Company common stock include associated preferred stock rights.
F2: Includes 13,272 shares of restricted stock acquired under the Nonemployee Director Stock Ownership Plan of the issuer. Restrictions are as authorized by the Board of Directors. The plan provides for tax withholding rights.
F3: The reporting person also indirectly beneficially owns 900 common shares of the issuer through a trust. The reporting person disclaims beneficial ownership of these shares.
ManpowerGroup Inc.
Report date January 01, 2019 · Filed January 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,982 |
Ending reported balance
After 2019-01-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-01-01 · Exercise / conversion · Acquired 3,097 · Balance 3,097 F1: Settlement of shares of deferred stock in shares of ManpowerGroup common stock on a 1 for 1 basis. Row 2 · 2019-01-01 · Exercise / conversion · Acquired 1,119 · Balance 4,216 F1: Settlement of shares of deferred stock in shares of ManpowerGroup common stock on a 1 for 1 basis. Row 3 · 2019-01-01 · Exercise / conversion · Acquired 1,766 · Balance 5,982 F1: Settlement of shares of deferred stock in shares of ManpowerGroup common stock on a 1 for 1 basis. |
| Deferred StockSEC Table II · derivative / convertible security | Direct | 2,469 |
Reported balance
After 2019-01-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-01-01 · Grant · Acquired 2,469 · Balance 2,469 F2: The shares of deferred stock vest in quarterly installments on the last day of each calendar quarter during 2019 and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2022 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions (as defined below). F3: Annual grant of deferred stock under the 2011 Equity Incentive Plan of the Company (the "Plan") and the Terms and Conditions Regarding the Grant of Awards to Non-Employee Directors under the Plan (the "Terms and Conditions"). F4: Represents the Market Price (as defined in the Plan) on the last trading day of 2018. |
| Deferred StockSEC Table II · derivative / convertible security | Direct | 1,307 |
Reported balance
After 2019-01-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-01-01 · Grant · Acquired 1,307 · Balance 1,307 F5: These shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 bases on the earlier of January 1, 2022 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F6: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of 100% of the Retainer (as defined in the Terms and Conditions) for 2018. F7: Represents the Average Trading Price (as defined in the Terms and Conditions). |
| Deferred StockSEC Table II · derivative / convertible security | Direct | 3,097 |
Reported balance
After 2019-01-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-01-01 · Grant · Acquired 69 · Balance 3,097 F8: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F9: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7: Represents the Average Trading Price (as defined in the Terms and Conditions). |
| Deferred StockSEC Table II · derivative / convertible security | Direct | 1,119 |
Reported balance
After 2019-01-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-01-01 · Grant · Acquired 25 · Balance 1,119 F8: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F9: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7: Represents the Average Trading Price (as defined in the Terms and Conditions). |
| Deferred StockSEC Table II · derivative / convertible security | Direct | 1,766 |
Reported balance
After 2019-01-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-01-01 · Grant · Acquired 40 · Balance 1,766 F8: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F9: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7: Represents the Average Trading Price (as defined in the Terms and Conditions). |
| Deferred StockSEC Table II · derivative / convertible security | Direct | 3,501 |
Reported balance
After 2019-01-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-01-01 · Grant · Acquired 79 · Balance 3,501 F10: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2020 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F9: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7: Represents the Average Trading Price (as defined in the Terms and Conditions). |
| Deferred StockSEC Table II · derivative / convertible security | Direct | 1,287 |
Reported balance
After 2019-01-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-01-01 · Grant · Acquired 29 · Balance 1,287 F10: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2020 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F9: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7: Represents the Average Trading Price (as defined in the Terms and Conditions). |
| Deferred StockSEC Table II · derivative / convertible security | Direct | 1,697 |
Reported balance
After 2019-01-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-01-01 · Grant · Acquired 38 · Balance 1,697 F10: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2020 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F9: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7: Represents the Average Trading Price (as defined in the Terms and Conditions). |
| Deferred StockSEC Table II · derivative / convertible security | Direct | 1,298 |
Reported balance
After 2019-01-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-01-01 · Grant · Acquired 29 · Balance 1,298 F11: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2021 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F9: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7: Represents the Average Trading Price (as defined in the Terms and Conditions). |
| Deferred StockSEC Table II · derivative / convertible security | Direct | 893 |
Reported balance
After 2019-01-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-01-01 · Grant · Acquired 20 · Balance 893 F11: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2021 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F9: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7: Represents the Average Trading Price (as defined in the Terms and Conditions). |
| Deferred StockSEC Table II · derivative / convertible security · Expires 2019-01-01 | Direct | 0 |
Reported balance
After 2019-01-01 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-01-01 · Exercise / conversion · Disposed 3,097 · Balance 0 F8: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F1: Settlement of shares of deferred stock in shares of ManpowerGroup common stock on a 1 for 1 basis. |
| Deferred StockSEC Table II · derivative / convertible security · Expires 2019-01-01 | Direct | 0 |
Reported balance
After 2019-01-01 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2019-01-01 · Exercise / conversion · Disposed 1,119 · Balance 0 F8: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F1: Settlement of shares of deferred stock in shares of ManpowerGroup common stock on a 1 for 1 basis. |
| Deferred StockSEC Table II · derivative / convertible security · Expires 2019-01-01 | Direct | 0 |
Reported balance
After 2019-01-01 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2019-01-01 · Exercise / conversion · Disposed 1,766 · Balance 0 F8: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F1: Settlement of shares of deferred stock in shares of ManpowerGroup common stock on a 1 for 1 basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Settlement of shares of deferred stock in shares of ManpowerGroup common stock on a 1 for 1 basis.
F2: The shares of deferred stock vest in quarterly installments on the last day of each calendar quarter during 2019 and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2022 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions (as defined below).
F3: Annual grant of deferred stock under the 2011 Equity Incentive Plan of the Company (the "Plan") and the Terms and Conditions Regarding the Grant of Awards to Non-Employee Directors under the Plan (the "Terms and Conditions").
F4: Represents the Market Price (as defined in the Plan) on the last trading day of 2018.
F5: These shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 bases on the earlier of January 1, 2022 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions.
F6: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of 100% of the Retainer (as defined in the Terms and Conditions) for 2018.
F7: Represents the Average Trading Price (as defined in the Terms and Conditions).
F8: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions.
F9: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends.
F10: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2020 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions.
F11: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2021 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2006 Filed Sep 26, 2006 22:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,796 | $0.00 Strike: $24.20 | $0.00 |
DisclosureSEC source: 0001104659-06-063205 · a4.xml · derivative · entry 6 WALTER JOHN R · CIK 0001046302 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,796 shares Expires 2006-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program. Read SEC document |
| September 22, 2006 Filed Sep 26, 2006 22:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,870 | $0.00 Strike: $23.23 | $0.00 |
DisclosureSEC source: 0001104659-06-063205 · a4.xml · derivative · entry 5 WALTER JOHN R · CIK 0001046302 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,870 shares Expires 2006-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program. Read SEC document |
| September 22, 2006 Filed Sep 26, 2006 22:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,796 | $24.20 | $43,463.02 |
DisclosureSEC source: 0001104659-06-063205 · a4.xml · nonDerivative · entry 2 WALTER JOHN R · CIK 0001046302 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2006 Filed Sep 26, 2006 22:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,870 | $23.23 | $43,443.65 |
DisclosureSEC source: 0001104659-06-063205 · a4.xml · nonDerivative · entry 1 WALTER JOHN R · CIK 0001046302 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2006 Filed May 2, 2006 21:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-06-030324 · a4.xml · nonDerivative · entry 1 WALTER JOHN R · CIK 0001046302 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,602 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| March 01, 2006 Filed Apr 4, 2006 14:05 UTC | DEERE & CO DE · Entity 106 | Grant$1 Par Common Stock | 974 | $76.95 | $74,949.30 |
DisclosureSEC source: 0000315189-06-000035 · primary_doc.xml · nonDerivative · entry 1 WALTER JOHN R · CIK 0001046302 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,272 F1 · security: References to Deere & Company common stock include associated preferred stock rights. F2 · balance_after: Includes 13,272 shares of restricted stock acquired under the Nonemployee Director Stock Ownership Plan of the issuer. Restrictions are as authorized by the Board of Directors. The plan provides for tax withholding rights. F3 · balance_after: The reporting person also indirectly beneficially owns 900 common shares of the issuer through a trust. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| July 07, 2005 Filed Jul 11, 2005 16:26 UTC | DEERE & CO DE · Entity 106 | Grant$1 Par Common Stock | 97 | $66.96 | $6,494.64 |
DisclosureSEC source: 0000315189-05-000052 · primary_doc.xml · nonDerivative · entry 1 WALTER JOHN R · CIK 0001046302 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,298 F1 · security: Reference to Deere & Company common stock includes associated preferred stock rights. F2 · balance_after: Includes 12,298 shares of restricted stock acquired under the Nonemployee Director Stock Ownership Plan of the issuer. Restrictions are as authorized by the Board of Directors. The plan provides for tax withholding rights. Read SEC document |
| April 22, 2005 Filed Apr 26, 2005 21:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-05-018226 · a4.xml · nonDerivative · entry 1 WALTER JOHN R · CIK 0001046302 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,475 F1 · security: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program). F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| March 02, 2005 Filed Mar 3, 2005 20:35 UTC | DEERE & CO DE · Entity 106 | Grant$1 Par Common Stock | 918 | $70.79 | $64,985.22 |
DisclosureSEC source: 0000315189-05-000022 · primary_doc.xml · nonDerivative · entry 1 WALTER JOHN R · CIK 0001046302 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,201 F1 · security: Reference to Deere & Company common stock includes associated preferred stock rights. F2 · balance_after: Includes 12,201 shares of restricted stock acquired under the Nonemployee Director Stock Ownership Plan of the issuer. Restrictions are as authorized by the Board of Directors. The Plan provides for tax withholding rights. F3 · balance_after: The reporting person also indirectly beneficially owns 900 common shares of the issuer through a trust. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| May 03, 2004 Filed May 5, 2004 22:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock equivalent units · Derivative | 1,722 | $42.32 Strike: $0.00 | $72,875.04 |
DisclosureSEC source: 0001104659-04-012727 · a4.xml · derivative · entry 1 WALTER JOHN R · CIK 0001046302 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,722 Underlying: common shares · 1,722 shares Expires not disclosed F1 · derivative.exercise_price: A stock equivalent unit account is maintained for the director for the deferral of director fees. These additional stock equivalent units were credited to that account. They resulted from the conversion into stock equivalent units of the deemed distribution of Hospira common stock, in connection with the spin-off of Hospira, Inc. from Abbott, based on the closing price of Abbott and Hospira common stock on May 3, 2004. Units are paid in cash. F1 · kind: A stock equivalent unit account is maintained for the director for the deferral of director fees. These additional stock equivalent units were credited to that account. They resulted from the conversion into stock equivalent units of the deemed distribution of Hospira common stock, in connection with the spin-off of Hospira, Inc. from Abbott, based on the closing price of Abbott and Hospira common stock on May 3, 2004. Units are paid in cash. F1 · derivative.exercise_date: A stock equivalent unit account is maintained for the director for the deferral of director fees. These additional stock equivalent units were credited to that account. They resulted from the conversion into stock equivalent units of the deemed distribution of Hospira common stock, in connection with the spin-off of Hospira, Inc. from Abbott, based on the closing price of Abbott and Hospira common stock on May 3, 2004. Units are paid in cash. F1 · derivative.expiration_date: A stock equivalent unit account is maintained for the director for the deferral of director fees. These additional stock equivalent units were credited to that account. They resulted from the conversion into stock equivalent units of the deemed distribution of Hospira common stock, in connection with the spin-off of Hospira, Inc. from Abbott, based on the closing price of Abbott and Hospira common stock on May 3, 2004. Units are paid in cash. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 19:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 5,825 | $0.00 Strike: $41.20 | $0.00 |
DisclosureSEC source: 0001104659-04-011397 · a4.xml · derivative · entry 4 WALTER JOHN R · CIK 0001046302 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,825 Underlying: common shares · 5,825 shares Expires 2014-04-22 F4 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b). It contains a replacement option feature. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 19:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,577 | $41.20 | $64,972.40 |
DisclosureSEC source: 0001104659-04-011397 · a4.xml · nonDerivative · entry 1 WALTER JOHN R · CIK 0001046302 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,586 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 03, 2004 Filed Mar 5, 2004 16:47 UTC | DEERE & CO DE · Entity 106 | Grant$1 Par Common Stock | 1,003 | $64.79 | $64,984.37 |
DisclosureSEC source: 0000315189-04-000041 · primary_doc.xml · nonDerivative · entry 1 WALTER JOHN R · CIK 0001046302 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,283 F1 · security: Reference to Deere & Company common stock includes associated preferred stock rights. F2 · balance_after: Includes 11,283 shares of restricted stock acquired under the Nonemployee Director Stock Ownership Plan of the issuer. Restrictions are as authorized by the Board of Directors. The Plan provides for tax withholding rights. F3 · balance_after: The reporting person also indirectly beneficially owns 900 common shares of the issuer through a trust. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.